Staff Reports
Two recent developments should have set off alarm bells about vaccine safety monitoring and the integrity of the Food and Drug Administration. One came from a Senate probe that released internal agency records. The other came from a major newspaper showing FDA officials told scientists to pull vaccine safety papers. The strange part is how the media treated the two stories very differently.
Two stories, two different treatments
The Senate Permanent Subcommittee on Investigations released an interim report and held a hearing called “Unmasked.” It says an FDA safety expert used a better way to mine safety data and found many signals the agency’s method missed. At the same time, the New York Times reported that FDA officials told staff to withdraw or block publication of vaccine safety studies. Both stories raise big questions. Yet one story was treated like a national scandal and the other barely made a ripple in many outlets.
Unmasked: what the Senate report says
The Senate report centers on Ana Szarfman, a long‑time FDA safety data expert. Her method adjusted for “masking” in adverse‑event data and reportedly revealed about two dozen significant safety signals that the FDA’s default approach missed. The committee released hundreds of pages of emails and analyses showing agency officials told her to stop sending those reports. One internal message warned the findings could “feed into anti‑vaccination rhetoric.” That sounds more like PR management than patient safety.
Blocked studies: what the New York Times revealed
Separately, reporters showed FDA staff were instructed to withdraw two COVID‑vaccine safety manuscripts that had been accepted or presented. One of the studies is available as a preprint and looked at older Americans on Medicare. It found only one clear concern — a very rare anaphylaxis signal — and otherwise no new safety alarms among millions of records. HHS said the papers were withdrawn because the authors “drew broad conclusions not supported by the data.” Fine. But why the heavy hand from agency leadership instead of an independent scientific review?
Why the double standard matters
It is hard to ignore the politics. Senator Ron Johnson’s committee released the Szarfman materials and held a hearing. The New York Times story about the withdrawn papers got broad pickup. Coverage was uneven. That matters because public trust in vaccines and regulators rests on transparency. If the agency silences a scientist who finds potential signals, but aggressively polices studies that show vaccines are safe, people will smell something rotten. Commissioner Makary, NIH Director Bhattacharya, and HHS Secretary Robert F. Kennedy Jr. should not be allowed to dodge independent review when trust is on the line.
Call for transparency and independent review
This should be simple: publish the full analyses, release the records, and let independent epidemiologists and statisticians judge the methods. If the Szarfman signals are false positives, fine — show the math and explain it. If the withdrawn studies had methodological problems, explain that publicly in plain language. No more secret edits and whispered memos about “anti‑vaccination rhetoric.” The American people deserve clarity, not spin. Trust is earned, and right now the FDA needs to earn it back.
